Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy
David Gyori, … , Len R. Stephens, Phillip T. Hawkins
David Gyori, … , Len R. Stephens, Phillip T. Hawkins
Published June 7, 2018
Citation Information: JCI Insight. 2018;3(11):e120631. https://doi.org/10.1172/jci.insight.120631.
View: Text | PDF
Research Article Immunology Oncology

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

  • Text
  • PDF
Abstract

Redundancy and compensation provide robustness to biological systems but may contribute to therapy resistance. Both tumor-associated macrophages (TAMs) and Foxp3+ regulatory T (Treg) cells promote tumor progression by limiting antitumor immunity. Here we show that genetic ablation of CSF1 in colorectal cancer cells reduces the influx of immunosuppressive CSF1R+ TAMs within tumors. This reduction in CSF1-dependent TAMs resulted in increased CD8+ T cell attack on tumors, but its effect on tumor growth was limited by a compensatory increase in Foxp3+ Treg cells. Similarly, disruption of Treg cell activity through their experimental ablation produced moderate effects on tumor growth and was associated with elevated numbers of CSF1R+ TAMs. Importantly, codepletion of CSF1R+ TAMs and Foxp3+ Treg cells resulted in an increased influx of CD8+ T cells, augmentation of their function, and a synergistic reduction in tumor growth. Further, inhibition of Treg cell activity either through systemic pharmacological blockade of PI3Kδ, or its genetic inactivation within Foxp3+ Treg cells, sensitized previously unresponsive solid tumors to CSF1R+ TAM depletion and enhanced the effect of CSF1R blockade. These findings identify CSF1R+ TAMs and PI3Kδ-driven Foxp3+ Treg cells as the dominant compensatory cellular components of the immunosuppressive tumor microenvironment, with implications for the design of combinatorial immunotherapies.

Authors

David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins

×

Figure 2

CSF1R+ tumor-associated macrophages inhibit CD8+ T cells of the adaptive immune system.

Options: View larger image (or click on image) Download as PowerPoint
CSF1R+ tumor-associated macrophages inhibit CD8+ T cells of the adaptive...
(A) In vivo growth curves of WT and Csf1–/– MC38 tumor cells implanted s.c. at day 0 into WT and Rag2–/– mice. (B and C) Quantification of the F4/80+ (B) and CD8+ (C) immune cells infiltrating the WT and Csf1–/– tumors isolated from the WT and Rag2–/– mice at day 21. (D) WT and Csf1–/– MC38 primary tumor masses removed at day 21 from WT mice treated with anti-CD8 antibody or control antibody. (E and F) Quantification of the CSF1R+ (E) and CD8+ (F) immune cells infiltrating the WT and Csf1–/– tumors isolated from the WT mice treated with anti-CD8 or control antibody at day 21. (G and H) Representative photomicrographs of (G) and PD-L1 expression on (H) BMDMs cultured in the presence of recombinant CSF1 or MC38 tumor supernatant and of primary CSF1R+ TAMs isolated from the MC38 primary tumors. (I and J) Representative flow panels (I) and quantification (J) of the in vitro proliferation of CD8+ lymphocytes co-cultured with BMDMs (as treated above) or CSF1R+ TAMs isolated from the MC38 tumors. Graphs show mean ± SEM of data from at least 3 independent experiments or 5–6 individual mice per group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., non-significant by Student’s t test or 2-way ANOVA. Scale bars: 50 μm.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts